Difference between revisions of "CD56"
Jump to navigation
Jump to search
(→Positive: +RCC occasionally) |
|||
| Line 19: | Line 19: | ||
==Occasionally positive== | ==Occasionally positive== | ||
*[[Renal cell carcinoma]] ~18% of cases.<ref name=pmid20462442>{{cite journal | | *[[Renal cell carcinoma]] ~18% of cases.<ref name=pmid20462442>{{cite journal |authors=Ronkainen H, Soini Y, Vaarala MH, Kauppila S, Hirvikoski P |title=Evaluation of neuroendocrine markers in renal cell carcinoma |journal=Diagn Pathol |volume=5 |issue= |pages=28 |date=May 2010 |pmid=20462442 |pmc=2876076 |doi=10.1186/1746-1596-5-28 |url=}}</ref> | ||
==See also== | ==See also== | ||
Revision as of 13:24, 1 June 2020
CD56 is a commonly available immunostain that is seen in a number of tumours. It is a sensitive marker of neuroendocrine differentiation.
Positive
Carcinomas
Lymphoid
- Acute myeloid leukemia.[2]
- Chronic myeloid leukemia.[2]
- Extranodal NK/T-cell lymphoma, nasal type.
- Hepatosplenic T-cell lymphoma.
Others
Occasionally positive
- Renal cell carcinoma ~18% of cases.[4]
See also
References
- ↑ Kurokawa, M.; Nabeshima, K.; Akiyama, Y.; Maeda, S.; Nishida, T.; Nakayama, F.; Amano, M.; Ogata, K. et al. (May 2003). "CD56: a useful marker for diagnosing Merkel cell carcinoma.". J Dermatol Sci 31 (3): 219-24. PMID 12727026.
- ↑ 2.0 2.1 URL: http://www.nordiqc.org/Epitopes/CD56/CD56.htm. Accessed on: September 13, 2014.
- ↑ Bahrami, A.; Gown, AM.; Baird, GS.; Hicks, MJ.; Folpe, AL. (Jul 2008). "Aberrant expression of epithelial and neuroendocrine markers in alveolar rhabdomyosarcoma: a potentially serious diagnostic pitfall.". Mod Pathol 21 (7): 795-806. doi:10.1038/modpathol.2008.86. PMID 18487991.
- ↑ Ronkainen H, Soini Y, Vaarala MH, Kauppila S, Hirvikoski P (May 2010). "Evaluation of neuroendocrine markers in renal cell carcinoma". Diagn Pathol 5: 28. doi:10.1186/1746-1596-5-28. PMC 2876076. PMID 20462442. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876076/.